Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

A Novel Aggressive NK Cell Leukemia Cell Line and Mouse Model for Evaluation of Therapeutic Candidates

Xiaoxian Zhao, Caroline Astbury, Feng Lin, Darren C. Phillips, Eric D. Hsi

Blood (2021) 138 (Supplement 1): 1198.

https://doi.org/10.1182/blood-2021-146645

Published: 2021

Journal Articles

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Xiaoxian Zhao, PhD, Bartlomiej Przychodzen, Juraj Bodo, PhD, Lisa Durkin, Daniel Lindner, MD PhD, Neetha Parameswaran, PhD, Michael Clemente, MS, Sarah L. Ondrejka, DO, Jaroslaw P. Maciejewski, MD PhD, Deepa Jagadeesh, MDMPH, Eric D. Hsi, MD

Blood (2019) 134 (Supplement_1): 1572.

https://doi.org/10.1182/blood-2019-129131

Published: 2019

Journal Articles

Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Neetha Parameswaran, PhD, Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Lisa Durkin, Yvonne Parker, Daniel Lindner, MD PhD, Eric D. Hsi, MD, Deepa Jagadeesh, MDMPH

Blood (2019) 134 (Supplement_1): 1515.

https://doi.org/10.1182/blood-2019-131800

Published: 2019

Journal Articles

Inhibition of Cyclin Dependent Kinase 9 Synergistically Enhanced Venetoclax Activity in Mantle Cell Lymphoma Cells

Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Ruoying Chen, PhD, Lisa Durkin, Andrew J. Souers, PhD, Darren C. Phillips, PhD, Eric D. Hsi, MD

Blood (2016) 128 (22): 1593.

https://doi.org/10.1182/blood.V128.22.1593.1593

Published: 2016

Journal Articles

The Synergistic Effect of Venetoclax Combined with a CDK9 Inhibitor in Primary Diffuse Large B Cell Lymphoma and Follicular Lymphoma Cells

Xiaoxian Zhao, PhD, Darren C. Phillips, PhD, Andrew J. Souers, PhD, Juraj Bodo, PhD, Paul Tapang, Daniel H Albert, PhD, Lisa Durkin, Eric D. Hsi, MD

Blood (2015) 126 (23): 2746.

https://doi.org/10.1182/blood.V126.23.2746.2746

Published: 2015

Journal Articles

CCMCL1: a new model of aggressive mantle cell lymphoma

Xiaoxian Zhao, Selina Chen-Kiang, Shashirekha Shetty, Maurizio Di Liberto, Juraj Bodo, Lisa Durkin, Ken Eng, Olivier Elemento, Mitchell R. Smith, Eric D. Hsi

Blood (2015) 125 (17): 2730–2732.

https://doi.org/10.1182/blood-2015-01-622795

Published: 2015

Includes: Supplemental data

Journal Articles

Activity of ABT-199 and Acquired Resistance in Follicular Lymphoma Cells

Juraj Bodo, PhD, Xiaoxian Zhao, PhD, Mitchell R. Smith, MD PhD, Eric D. Hsi, MD

Blood (2014) 124 (21): 3635.

https://doi.org/10.1182/blood.V124.21.3635.3635

Published: 2014

Journal Articles

Combination Of Ibrutinib With ABT-199, a BCL-2 Pathway Inhibitor: Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model

Xiaoxian Zhao, PhD, Juraj Bodo, PhD, Danyu Sun, MD, PhD, Jeffrey J. Lin, PhD, Lisa Durkin, Shashirekha Shetty, PhD, Mitchell R. Smith, MD, PhD, Eric D. Hsi, MD

Blood (2013) 122 (21): 645.

https://doi.org/10.1182/blood.V122.21.645.645

Published: 2013

Journal Articles

The PI3K Inhibitor GS-1101 (CAL-101) Synergistically Potentiates HDAC-Induced Proliferation Inhibition and Apoptosis Through the Activation of JNK in Lymphoma Cells

Juraj Bodo, PhD, Brian T. Hill, MD, PhD, Xiaoxian Zhao, PhD, Craig A. Portell, MD, Brian J. Lannutti, PhD, Eric D. Hsi, MD

Blood (2012) 120 (21): 3714.

https://doi.org/10.1182/blood.V120.21.3714.3714

Published: 2012

Journal Articles

Phospho-SFKs (Y416) As a Potential Predictive Marker for Dasatinib Therapy in B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia,

Xiaoxian Zhao, Ph.D., Eric D. Hsi, MD

Blood (2011) 118 (21): 3727.

https://doi.org/10.1182/blood.V118.21.3727.3727

Published: 2011

Journal Articles

CD37 Is a Potential Therapeutic Target for B-Cell Non-Hodgkin Lymphoma

Xiaoxian Zhao, PhD., Suzanne Ybarra, Lisa Durkin, Mien Sho, Neeraj Kumar, Brian Gordon, Paul Algate, Gary Starling, PhD, Debra Chao, Ph.D., Eric Hsi, MD

Blood (2010) 116 (21): 3098.

https://doi.org/10.1182/blood.V116.21.3098.3098

Published: 2010

Journal Articles

The Myeloid Cell Surface Receptor IREM-1: A Novel Monoclonal Antibody Target for Acute Myeloid Leukemia (AML)

Xiaoxian Zhao, Wouter Korver, Shweta Singh, Cecile Pardoux, Eric D. Hsi, Arie Abo

Blood (2008) 112 (11): 2933.

https://doi.org/10.1182/blood.V112.11.2933.2933

Published: 2008

Journal Articles

Distinct Role of Src Family Kinase Inhibitors in Burkitt Lymphoma Cells Vs. Diffuse Large B-Cell Lymphoma Cells

Xiaoxian Zhao, Andrew E. Schade, Eric Hsi

Blood (2008) 112 (11): 3765.

https://doi.org/10.1182/blood.V112.11.3765.3765

Published: 2008

Journal Articles

CLL-1, a Receptor Expressed on Myeloid Leukemic Stem Cells, Is a Potential Target for Immunotherapy of AML

Wouter Korver, PhD, Xiaoxian Zhao, Shweta Singh, Cecile Pardoux, Jingsong Zhao, Siddhartha Sen, Monica L. Guzman, PhD, Craig T. Jordan, PhD, Eric D Hsi, MD, Arie Abo

Blood (2008) 112 (11): 4003.

https://doi.org/10.1182/blood.V112.11.4003.4003

Published: 2008

Journal Articles

Potent Anti-Cancer Activity of Anti-NTB-a Monoclonal Antibodies in Preclinical Leukemia and Lymphoma Models

Wouter Korver, PhD, Xiaoxian Zhao, Shweta Singh, Cecile Pardoux, Ishita Barman, Gerard Aguilar, Jingsong Zhao, Eric Hsi, MD, Arie Abo

Blood (2008) 112 (11): 4975.

https://doi.org/10.1182/blood.V112.11.4975.4975

Published: 2008

Journal Articles

IREM-1 Is a Cell Surface Receptor Expressed in AML Blasts: Potential for Targeted Immunotherapy in AML.

Xiaoxian Zhao, PhD, Wouter Korver, Ph.D., Shweta Singh, Eric D. Hsi, M.D., Arie Abo, Ph.D.

Blood (2007) 110 (11): 1792.

https://doi.org/10.1182/blood.V110.11.1792.1792

Published: 2007

Journal Articles

The Lymphoid Cell Surface Receptor NTB-A: A Novel Monoclonal Antibody Target for Leukemia and Lymphoma Therapeutics.

Wouter Korver, PhD, Shweta Singh, PhD, Xiaoxian Zhao, PhD, Eric D. Hsi, MD, Arie Abo, PhD

Blood (2007) 110 (11): 4511.

https://doi.org/10.1182/blood.V110.11.4511.4511

Published: 2007

Journal Articles

CLL-1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia.

Wouter Korver, Xiaoxian Zhao, Shweta Singh, Eric D. Hsi, Arie Abo

Blood (2007) 110 (11): 2839.

https://doi.org/10.1182/blood.V110.11.2839.2839

Published: 2007

Journal Articles

Expression of NTB-A in Normal Tissue, Non-Hodgkin Lymphomas and Investigation of Its Potential Therapeutic Impact for Chronic Lymphocytic Leukemia.

Xiaoxian Zhao, PhD, Wouter Korver, Ph.D., Nichole Prescott, M.S., Arie Abo, Ph.D., Eric Hsi, M.D.

Blood (2006) 108 (11): 4741.

https://doi.org/10.1182/blood.V108.11.4741.4741

Published: 2006

NARROW

A Novel Aggressive NK Cell Leukemia Cell Line and Mouse Model for Evaluation of Therapeutic Candidates

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab

Inhibition of Cyclin Dependent Kinase 9 Synergistically Enhanced Venetoclax Activity in Mantle Cell Lymphoma Cells

The Synergistic Effect of Venetoclax Combined with a CDK9 Inhibitor in Primary Diffuse Large B Cell Lymphoma and Follicular Lymphoma Cells

CCMCL1: a new model of aggressive mantle cell lymphoma

Activity of ABT-199 and Acquired Resistance in Follicular Lymphoma Cells

Combination Of Ibrutinib With ABT-199, a BCL-2 Pathway Inhibitor: Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model

The PI3K Inhibitor GS-1101 (CAL-101) Synergistically Potentiates HDAC-Induced Proliferation Inhibition and Apoptosis Through the Activation of JNK in Lymphoma Cells

Phospho-SFKs (Y416) As a Potential Predictive Marker for Dasatinib Therapy in B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia,

CD37 Is a Potential Therapeutic Target for B-Cell Non-Hodgkin Lymphoma

The Myeloid Cell Surface Receptor IREM-1: A Novel Monoclonal Antibody Target for Acute Myeloid Leukemia (AML)

Distinct Role of Src Family Kinase Inhibitors in Burkitt Lymphoma Cells Vs. Diffuse Large B-Cell Lymphoma Cells

CLL-1, a Receptor Expressed on Myeloid Leukemic Stem Cells, Is a Potential Target for Immunotherapy of AML

Potent Anti-Cancer Activity of Anti-NTB-a Monoclonal Antibodies in Preclinical Leukemia and Lymphoma Models

IREM-1 Is a Cell Surface Receptor Expressed in AML Blasts: Potential for Targeted Immunotherapy in AML.

The Lymphoid Cell Surface Receptor NTB-A: A Novel Monoclonal Antibody Target for Leukemia and Lymphoma Therapeutics.

CLL-1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia.

Expression of NTB-A in Normal Tissue, Non-Hodgkin Lymphomas and Investigation of Its Potential Therapeutic Impact for Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only